Download fulltext HTML
Fathalla, M., Abdrabo, A. A., & Modawe, G. (2021). Evaluation of Serum Gonadotropin and Prolactin Level among Sudanese Patients with Chronic Renal Failure. Sudan Journal of Medical Sciences (SJMS), 16(3), 399–408. https://doi.org/10.18502/sjms.v16i3.9700

https://doi.org/10.18502/sjms.v16i3.9700

statistics

  • 841 Abstract Views
  • 424 PDF Views
  • 0 HTML Views
  • Cited by 2 articles

authors

  • Maha Fathalla

    Maha Fathalla

    Department of Clinical Chemistry, Faculty of Medical Laboratory Sciences, Alneelain University, Khartoum, Sudan
  • AbdElkarim A. Abdrabo

    AbdElkarim A. Abdrabo

    Department of Clinical Chemistry, Faculty of Medical Laboratory Sciences, Alneelain University, Khartoum, Sudan
  • GadAllah Modawe

    GadAllah Modawe

    Department of Biochemistry, Faculty of Medicine and Health Sciences, Omdurman Islamic University, Omdurman, Sudan

Published Date

  • Sep 30, 2021

Evaluation of Serum Gonadotropin and Prolactin Level among Sudanese Patients with Chronic Renal Failure

Sudan Journal of Medical Sciences (SJMS) / Sudan JMS: Volume 16 (2021), Issue No. 3 / Pages 399–408

Abstract

Background: Generally, patients on hemodialysis for chronic renal failure also have endocrine defects and sexual function disorders. In this study, we aimed to assess the serum prolactin (PRL), luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in patients with chronic renal failure.


Methods: This hospital-based case–control study was conducted at Jabal Aulia Teaching Hospital, Khartoum, Sudan. The study was carried out between August 2019 and February 2020. A total of 100 subjects were enrolled – 50 chronic renal failure patients and 50 as controls. The serum hormones were estimated using Tosoh 360. SPSS version 25 was used to analyze the results.


Results: The serum PRL, LH, and FSH were significantly increased among chronic renal failure patients than their healthy counterparts (p-value = 0.000). The age of patients was positive correlated with plasma hormones, PRL (r = 0.332, p = 0.001), LH (r = 0.387, p = 0.000), and FSH (r = 0.320, p = 0.001). No correlation was found between the duration of the disease and serum hormones.


Conclusion: Patients with chronic renal failure had a highly significant increase of serum PRL, LH, and FSH and also the age of the patients was positively correlated with serum hormones.


Keywords: chronic renal failure, prolactin, gonadotropin, hemodialysis

References
[1] Rathi, M. and Ramachandran, R. (2012). Sexual and gonadal dysfunction in chronic kidney disease: pathophysiology. Indian Journal of Endocrinology and Metabolism, vol. 16, no. 2, pp. 214–219.

[2] Finkelstein, S. H. and Finkelstein, F. O. (2002). Evaluation of sexual dysfunction in dialysis patients. In A. R. Nissenson and R. N. Fine (Eds), Dialysis therapy (3rd ed., pp. 368–373). Philadelphia: Hanley and Belfus.

[3] Biasioli, S., Mazzali, A., Foroni, R., et al. (1988). Chronobiological variations of prolactin (PRL) in chronic renal failure (CRF). Clinical Nephrology, vol. 30, pp. 86–92.

[4] Bommer, J., Ritz, E., del Pozo, E., et al. (1979). Improved sexual function in male haemodialysis patients on bromocriptine. Lancet, vol. 2, no. 8141, pp. 496–497.

[5] Schaefer, F., Vogel, M., Kerkhoff, G., et al. (2001). Experimental uraemia affects hypothalamic amino acidneurotransmitter milieu. Journal of the American Society of Nephrology, vol. 12, no. 6, pp. 1218–1227.

[6] Schaefer, F., van Kaick, B., Veldhuis, J. D., et al. (1994). Changes in the kinetics and biopotency of luteinizing hormone in hemodialyzed men during treatment with recombinant human erythropoietin. Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 1208–1215.

[7] Schaefer, F., Veldhuis, J. D., Robertson, W. R., et al. (1994). Immunoreactive and bioactive luteinizing hormone in pubertal patients with chronic renal failure. Kidney International, vol. 45, no. 5, pp. 1465–1476.

[8] Yilmaz, M. I., Sonmez, A., Qureshi, A. R., et al. (2011). Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clinical Journal of the American Society of Nephrology, vol. 6, no. 7, pp. 1617–1625.

[9] Dunkel, L., Raivio, T., Laine, J., et al. (1997). Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney International, vol. 51, no. 3, pp. 777–784.

[10] Carrero, J. J., Kyriazis, J., Sonmez, A., et al. (2012). Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clinical Journal of the American Society of Nephrology, vol. 7, no. 2, pp. 207–215.

[11] Reuwer, A. Q., Twickler, M. T., Hutten, B. A., et al. (2009). Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circulation. Cardiovascular Genetics, vol. 2, no. 4, pp. 389–395.

[12] Hylander, B. and Lehtihet, M. (2015). Testosterone and gonadotropins but not SHBG vary with CKD stages in young and middle aged men. Basic and Clinical Andrology, vol. 25, p. 9.

[13] El-Assaly, N. M., El-Ashry, N. I., Waked, E., et al. (2008). Gonadal dysfunction in chronic renal failure. Australian Journal of Basic and Applied Sciences, vol. 2, no. 3, pp. 481–487.

[14] Handelsman, D. J. (1985). Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocrine Reviews, vol. 6, no. 2, pp. 151–182.

[15] Dunkel, L., Raivio, T., Laine, J., et al. (1997). Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney International, vol. 51, no. 3, pp. 777–784.

[16] Adam, M. Y. M. and Ismail, A. M. (2019). Assessment of prolactin level among chronic renal failure patients in Khartoum State. Pathology and Laboratory Medicine, vol. 3, no. 1, pp. 1–4.

[17] Sobki, S. H., Al-Etah, H., El Gezeery, A., et al. (2004). Effect of age on pituitary gonadal hormonal responses in HD patients. Saudi Journal of Kidney Disease and Transplantation, vol. 15, no. 4, pp. 447–454.

[18] Wu, S. C., Lin, S. L., and Jeng, F. R. (2001). Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients. Scandinavian Journal of Urology and Nephrology, vol. 35, no. 2, pp. 136–140.

[19] Meachem, S. J., Nieschlag, E., and Simoni, M. (2001). Inhibin B in male reproduction: pathophysiology and clinical relevance. European Journal of Endocrinology, vol. 145, no. 5, pp. 561–571.

[20] Adam, M. Y. M. and Ismail A. M. (2019). Assessment of prolactin level among chronic renal failure patients in Khartoum State. Pathology and Laboratory Medicine, vol. 3, no. 1, pp. 1–4.

[21] Nehru, D., Kandasamy S, Chandrmouli, R. K., et al. (2016). Evaluation of serum prolactin level in chronic renal failure. Asian Journal of Pharmaceutical and Clinical Research, vol 9, no. 4, pp. 201–203.